CPRIT PDR — Texas New Technologies Company
Funds Texas oncology startups in emerging technologies, including digital and life science manufacturing pathways.
Eligibility · United States · US-TX
The Cancer Prevention and Research Institute of Texas (CPRIT) operates the Texas New Technologies Company RFA as part of its Product Development Research program, which allocates approximately $70 million per fiscal year to Texas-based oncology companies. This track specifically serves oncology-enabling technologies that do not fit the Therapeutics or Device/Diagnostics RFAs — covering bioinformatics, artificial intelligence applied to cancer, radionuclide therapies, cell-based therapy manufacturing, sample quality tools, and biomanufacturing platforms. Only for-profit companies may apply; nonprofit organizations, universities, and individual applicants are ineligible.
Award amounts for this track are not published as a fixed ceiling, unlike the Seed RFA. Projects run for three years with extension possible to fully expend awarded funds. A matching-funds contribution from the company and a revenue-sharing agreement — structured as royalties, equity, or other mechanisms — are required at contract execution, reflecting the Texas General Obligation bond backing that underlies CPRIT's grant portfolio. Companies headquartered outside Texas may apply but must commit in writing to relocate to Texas before an award is executed.
Applications are accepted on a rolling basis through the cpritgrants.org portal. The two-stage process begins with a preliminary package — a two-page executive summary, a 16-slide pitch deck, and a one-page aims and budget summary — which the Product Development Review Council (PDRC) evaluates within three to five weeks. Invited applicants then submit a full application and present to a review panel via video conference. Due diligence by outside contractors covering IP, regulatory strategy, manufacturability, and market analysis follows before the Oversight Committee votes, requiring a two-thirds majority to approve each award. All reviewers live and work outside Texas to eliminate in-state conflicts of interest.
Oncology-enabling technologies — bioinformatics, AI, radionuclides, cell-based therapy manufacturing, sample quality tools, and biomanufacturing — not fitting the therapeutics or device tracks.
Sign up free to see the funding breakdown
Sign up free to see the industries in scope
Sign up free to see the full eligibility
Sign up free to see how to apply
Sign up free to see what you submit
Sign up free to see the timeline